gdc
Multiple MyelomaSide-Effects Management

Potential Side Effects and How to Treat

Jack Aiello shares his experience on orals, and the significance of informing patients of the side effects and mitigating them.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

It's actually been a long time since my medical team gave me some information with respect to an oral treatment. That said, what is helpful is that they gave me the detailed understanding of things I previously discussed. When should I be taking it, how often?

For example, I was on an oral treatment called thalidomide. Thalidomide tended to make you sleepy. The recommendation was take it before you go to bed and you will get a fine night's sleep, which you did. That was an important recommendation as opposed to taking it in the morning and you're sleepwalking through the day.

I think that it's also important that they at least make you aware of potential side effects. The issue if someone says, "Well, this is going to cause some stomach ache," is that with the patient, once they take it, if they get a stomach ache, they make think, "Oh, that drug has caused it. It may have. It's more important to have complete information.

If I might get a suspected skin rash, if I might have some type of other side effect, it's important for doctors to share that information and furthermore, what to do if that happens.

There may be drugs that I should be taking prophylactically to prevent those side effects from occurring and maybe I am. Maybe those dosages should be increased, or not. Doctors can help you make sure that the side effects you experience are minimal.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 31, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country